|
*Promoted by Interactive Offers |
There is a stock that has been breaking out over the last couple of days I want to talk about this morning with you. |
I think there could be the start of something very big over the coming months. |
You have probably probably heard about the new outbreaks of "Bird Flu," and seen headlines like this one on Forbes, popping up everywhere lately… |
|
This morning, I did a quick scan on the search activity for "Bird Flu" related searches, and it is shocking how many people are worried about this developing into a new pandemic. |
That's the bad, scary news. |
But, there is a bright spot right now, and it could be an incredible opportunity in the making. |
Pull up NanoViricides (NNVC) on your platform right now, and let's look at what's going on. |
While we all know the scary story of the brewing pandemic – that currently doesn't have a cure – NNVC just announced that they have developed an antiviral drug that appears to be superior to the existing remedies, at least in early studies. |
Read the whole announcement for yourself, it is incredible. |
Pay particular attention to this line, "NanoViricides reports that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-influenza drugs." |
As you can imagine, the stock has been reacting very well since that announcement. |
|
But here is what I am wondering… What if NNVC is just getting started? |
When I search for traders talking about this story, the activity is certainly picking up, but it is far from "frothy" levels where you are hearing about it on mainstream media. |
If the market truly picks up on this story, I think we could have an absolute monster on our hands. |
I don't think the Bird Flu story is going away anytime soon, in fact, knowing how politics work, I would assume we will see a lot more coverage of the story to incite fear in voters headed into the election. |
There aren't a lot of stocks you can tie to this outbreak right now, and NNVC could emerge as the favorite for traders. |
Also, just moments ago, NNVC issued more news that could tie into this whole theme. |
Remember, NNVC is currently trading for just over $1. |
I am not going to debate valuations here, but I think you know what is possible from this level if this story really catches on with more traders. |
Consider some of these points on the stock as well… |
NanoViricides, Inc's lead drug, NV-387, is in Phase 1 clinical trials. Broad spectrum antiviral NV-387 showing promise against many virus families including and beyond Tripledemic (i.e. COVID-19, RSV, FLU) . No reported adverse events in Phase I SAD and MAD studies, even at the highest dose 40mg/Kg Found to be non-immunogenic, non-mutagenic, non-allergenic, and non-phototoxic. Strong safety allows use in pediatrics, adults with comorbidities, and immune-compromised patients, unlike the limitations of products currently in the market. Developed Oral Syrup and Oral Gummies (soft solids) - good for geriatric and pediatric patients Drugs are expected to continue to be effective even as the virus generates variants - unique receptor sites don't change Technology mimics unique receptor sites used by virus; delivers to specific targets using receptor-recognition (no bulky antibodies)
|
Now, spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration. |
Bottom line: While the stock might be a little stretched right now, it is impossible to know where a story like this will carry the price to. NNVC is a fast-developing situation and it should be on the radar of every trader right now 📡. |
I didn't have time this morning to look deeply into the amount of shares shorted in this stock, but I imagine that could be a considerable driving force as well. |
If someone has good data on that, can you reply to this email and let me know? |
I hope you have a great trading day. I'll be watching NNVC all day long. |
To Your Success, |
|
*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
P.S. I wanted to include an overview of TODAY's rundown of the biggest movers and shakers BELOW, complimentary from our friends at 360 Wall St. Great stuff! |
|
Today's Movers & Shakers from 360 Wall St |
RDDT - Up over 10% in the pre-market after better than expected first earnings report after IPO |
Reddit, Inc. (RDDT) operates a website that organizes digital communities. It organizes communities based on specific interests that enable users to engage in conversations by sharing experiences, submitting links, uploading images and videos, and replying to one another. |
In the after-hours yesterday, the company reported its first ever earnings after its recent IPO. |
Q1 2024 Revenue increased 48% to $243 million. Analysts, on average, estimated $211.9 million, according to data compiled by Bloomberg. |
The text-based social media company said it now has more than 82.7 million global daily users — a jump of 37% from a year earlier. |
Reddit reported a net loss of $575.1 million in the quarter compared with a loss of $60.9 million a year earlier. Adjusted earnings before interest, taxes, depreciation and amortization were $10 million, compared with a loss of $50.2 million in the quarter a year earlier. |
The stock traded up over 10% in the pre-market in reaction to the better than expected revenues and earnings release. |
|
The $54.50 area acted as support in the after-hours and will be an important level to watch. |
Above it, targets to the upside are $57.70, $58.30 and then the after-hours high at $60. Beyond that, $64 and $65.11 come into play. |
Below $54.50, targets to the downside are $51.25, $50 and then a gap fill at $49.40. |
|
CLOV - Up over 15% in pre after reporting better than expected earnings |
Clover Health Investments Corp. (CLOV) provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. |
In the after-hours yesterday, the company reported Q1 2024 earnings. |
Highlights included: |
First Quarter 2024 Insurance Revenue growth of 8% year-over-year |
First Quarter 2024 GAAP Net Loss from Continuing Operations of $23.2 million versus First Quarter 2023 loss of $79.7 million |
First Quarter Adjusted EBITDA profitability of $6.8 million versus prior period loss of $37.5 million |
Improved 2024 guidance to Insurance Revenue of $1.30 billion - $1.35 billion and Adjusted EBITDA profitability of $10 million - $30 million |
The market reacted positively to the results and better than expected guidance targeting full-year 2024 Adjusted EBITDA profitability. |
The stock traded up over 15% in the pre-market in reaction to the earnings report. |
|
The first target for bulls is the pre-market high at $0.90. |
Beyond that, $0.95, $1, $1.05, $1.10 and $1.15 come into play. |
Below $0.90, targets to the downside are $0.80 and then a gap fill at $0.74. |
|
ENVB - Up over 30% in pre after signing of non-binding term sheet with undisclosed licensee for exclusive license to patented methods of treating breast and other cancers using cannabinoids |
Enveric Biosciences Inc. (ENVB) is a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. |
In the pre-market this morning, the company announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company ("Licensee") to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers for development through additional discovery and preclinical stages using cannabinoids in combination with chemotherapeutic drugs to treat cancer. |
Assuming certain conditions are met, the Licensee will pay Enveric a License Execution Fee and development and sales milestones up to $61 Million, and royalties (ranging from 2.5% up to 10%) on all future sales. The Licensee also has a cash Buyout Option. |
The stock traded up over 30% in the pre-market in reaction to the news. |
|
The $1.05 area has acted as support in the pre-market and will be an important level to watch. |
Above it, targets to the upside are $1.10, $1.15 and then the pre-market high at $1.26. Beyond that, $1.50, $1.63 and $1.85 come into play. |
Below $1.05, targets to the downside are $1 and then a gap fill at $0.89. |
|
Questions or concerns about our products? Email Support@ragingbull.com |
© Copyright 2022, RagingBull |
|
*PAID ADVERTISEMENT. Raging Bull has currently been paid seventeen thousand five hundred dollars from Interactive Offers who was compensated by a third party not affiliated with the Company for advertising NanoViricides. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NanoViricides, increased trading volume, and possibly an increased share price of NanoViricides' securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NanoViricides, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. | SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. | Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull's business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. | TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. | NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch | | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company's financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. |
|
|
|
Post a Comment
Post a Comment